REVA Medical demonstrates successful MOTIV scaffold usage and clinical efficacy in BTK study at VIVA26
Executive summary: REVA Medical performed a successful live demonstration of a MOTIV scaffold procedure and released new clinical trial data at the VIVA26 conference. The data suggests higher efficacy rates for MOTIV compared to standard balloon angioplasty in Rutherford 4 and 5 CLTI patients, potentially shifting treatment standards for below-the-knee revascularization.
Who is involved: REVA Medical
Likely next (inference): Further clinical adoption and potential regulatory or reimbursement discussions based on the presented BTK study results.
REVA Medical has provided clinical validation for its MOTIV vascular scaffolds through a live demonstration of below-the-knee revascularization and new data from its BTK study. The findings indicate that the MOTIV device outperforms traditional balloon angioplasty in efficacy endpoints for specific CLTI patient populations. This presentation at VIVA26 serves as a critical milestone for the company's commercial positioning in the peripheral artery disease market.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Base: Expanded clinical adoption (60%)
Physicians increasingly opt for MOTIV scaffolds over balloon angioplasty for complex CLTI cases.
- Publication of full BTK study results in peer-reviewed journals
- Increased uptake in hospital procurement cycles
Upside: Market leadership in BTK (25%)
REVA Medical captures significant market share from legacy angioplasty providers.
- Inclusion in major clinical practice guidelines
- Large-scale institutional contracts
Downside: Clinical scrutiny (15%)
Further long-term data is required, slowing commercial momentum.
- Emergence of adverse event data in extended follow-ups
- Competitor release of superior clinical trial data
What to watch
- Full peer-reviewed publication of the BTK study results
- Post-VIVA26 sales volume or hospital procurement updates
- Clinical guideline updates regarding CLTI treatment protocols
Timeline
- — REVA Medical gibt erfolgreiche Live-Vorfuhrung eines MOTIV-Eingriffs und neue Ergebnisse der BTK-Studie auf der VIVA26 bekannt (PR Newswire)
- — REVA Medical anuncia una demostración exitosa de un caso en vivo con MOTIV® en VIVA26 (PR Newswire)
- — REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26 (PR Newswire)
Analysis — what this means
Sectors affected
- Vascular medical device manufacturing
- Peripheral Artery Disease (PAD) treatment providers
- Interventional cardiology/vascular surgery
Key entities
Sources
- REVA Medical gibt erfolgreiche Live-Vorfuhrung eines MOTIV-Eingriffs und neue Ergebnisse der BTK-Studie auf der VIVA26 bekannt — PR Newswire
- REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26 — PR Newswire
- REVA Medical anuncia una demostración exitosa de un caso en vivo con MOTIV® en VIVA26 — PR Newswire
Related cases
- REVA Medical’s live MOTIV demonstration and positive BTK trial results signal a potential shift in below‑the‑knee revascularization treatment that could boost device adoption and hospital cost savings
- Iyuno launches CLOE Skills, providing persistent context storage to unify localization across media
- PeproMene Bio reports breakthrough Phase 1 results for BAFF-R targeted CAR T-cell therapy in The Lancet
- Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by its Kangyueda product
- Mohawk Industries posts solid Q2 2026 profit, underscoring resilience in the flooring market